Short answer
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 5.02 (Departure/Election of Directors or Officers), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026.
Mineralys Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results and corporate update announced for quarter ended June 30, 2026
- Full results and management commentary contained in Exhibit 99.1 press release
Item 5.02 · Departure/Election of Directors or Officers
- James J. Ferguson III, M.D. appointed Chief Medical Officer effective August 10, 2026
- David Rodman, M.D. replaced as CMO but remains full-time Strategic Advisor
- Rodman no longer classified as an officer or executive officer under Exchange Act rules
- Employment agreement amended to reflect Rodman’s revised responsibilities
Item EX-99.1 · Exhibit EX-99.1
- Q2 2026 net loss $241.1M, driven by the $200.0M Tanabe upfront payment and higher commercial preparation costs
- Cash, equivalents and investments $661.4M, expected to fund operations through 2028 including lorundrostat launch
- FDA PDUFA target December 22, 2026 creates a key near-term approval catalyst for lorundrostat
- Financing added $150.0M gross equity proceeds and $100.0M debt, but increased senior secured loan liabilities to $97.6M
- Tanabe royalty elimination improves product economics, while retaining up to $255.0M commercial milestone obligations plus $10.0M for a second indication
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Mineralys Therapeutics, Inc. 8-K filings
Get the next MLYS 8-K as it lands
Follow MLYS for push alerts, or ask the research agent what this filing means.